Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R

Annals of Hematology

Volumn 89, Issue 4, 2010, Pages 399-404

  Xiao, Hui ^a   Xiao, Qi ^b   Zhang, Kejian ^a   Zuo, Xuelan ^a   Shrestha, Umid Kumar ^a  

^a WUHAN UNIVERSITY   (China)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

Curcumin; FA BRCA (Fanconi anemia BRCA) pathway; Multidrug resistance; Multiple myeloma

Indexed keywords

CURCUMIN; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA PROTEIN; MELPHALAN; NUCLEAR PROTEIN; PROTEIN BRCA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FANCD2 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UBIQUITINATION; WESTERN BLOTTING; CELL PROLIFERATION; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; HUMANS; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 77649283299     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0831-6     Document Type: Article

References (29)

1. Yang HH, Ma MH, Vescio RA et al (2003) Overcoming drug resistance in multiple myeloma:the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol 21:4239-4247
2. Kumar V, Varma N, Varma S et al (2004) Flow cytometric analysis of DNA indices, expression of p53 and multidrug resistance genes in multiple myeloma patients. Anal Quant Cytol Histol 26:271-277
3. Tai YT, Teoh G, Lin B et al (2000) Ku86 variant expression and function in multiple myeloma cells is associated with increased sentivity to DNA damage. J Immunol 165:6347-6355
4. Efferth T, Fabry U, Osieka R (2002) Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells. Anticancer Res 22:231-234
5. Mathew CG (2006) Fanconi anaemia genes and susceptibility to cancer. Oncogene 25:5875-5884
6. Taniguchi T, Tischkowitz M, Ameziane N et al (2003) Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9:568-574
7. Hannemann J, Oosterkamp HM, Bosch CA et al (2005) Changes in gene expression assiociated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 23:3331-3342
8. Mori H, Niwa K, Zheng Q et al (2001) Cell proliferation in cancer prevention; effects of preventive agents on estrogen-related endometrial carcinogenesis model and on an in vitro model in human colorectal cells. Mutat Res 480:201-207
9. Aggarwal BB, Kumar A, Bharti AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23:363-398
10. Ruffin MT, Normolle DP, Heath DD et al (2003) Dose escalation of curcumin in healthy adults. Cancer Epidem Biomar Prevent 12 (Part 2 Suppl. S):1324S
11. Sharma RA, Euden SA, Platton SL et al (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10:6847-6854
12. Garcea G, Berry DP, Jones DJL et al (2005) Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidem Biomar Prevent 14:120-125
13. Shi YQ, Qu XJ, Liao YX et al (2008) Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycin-resistant K562/A02 cells. Eur J Pharmacol 14:66-71
14. Wang J, Xia Y, Wang H et al (2007) Chinese herbs of Shenghe Powder reverse multidrug resistance of gastric carcinoma SGC-7901. Integr Cancer Ther 6:400-404
15. Dronkert ML, Kanaar R (2001) Repair of DNA interstrand crosslinks. Mutat Res 486:217-247
16. Nobili S, Landini I, Giglioni B et al (2006) Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7:861-879
17. Di Nicolantonio F, Mercer SJ, Knight LA (2005) Cancer cell adaptation to chemotherapy. BMC Cancer 5:78
18. D'Andrea AD, Grompe M (2003) The Fanconi anemia/BRCA pathway. Nat Rev Cancer 3:23-34
19. Sasaki MS, Takata M, Sonoda E et al (2004) Recombination repair pathway in the maintenance of chromosomal integrity against DNA interstrand crosslinks. Cytogenet Genome Res 104:28-34
20. Song XR, Hou SX (2005) Research progress in the reversion of traditional Chinese medicine on multidrug resistance of tumor. China J Chin Materia Medica 30:1300-1304
21. Shankar S, Ganapathy S, Chen Q et al (2008) Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer 29:16
22. Choi BH, Kim CG, Lim Y et al (2008) Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/ NF kappa B pathway. Cancer Lett 259:111-118
23. Dhandapani KM, Mahesh VB, Brann DW (2007) Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem 102:522-538
24. Limtrakul P (2007) Curcumin as chemosensitizer. Adv Exp Med Biol 595:269-300
25. Chan MM, Fong D, Soprano KJ et al (2003) Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J Cell Physiol 194:63-70
26. Garcea G, Berry DP, Jones DJ et al (2005) Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomark Prev 14:120-125
27. Garcea G, Jones DJ, Singh R et al (2004) Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 90:1011-1015
28. Sharma RA, Euden SA, Platton SL et al (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10:6847-6854
29. Sharma RA, McLelland HR, Hill KA et al (2001) Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7:1894-1900